4//SEC Filing
USMAN NASSIM 4
Accession 0001140361-24-024125
CIK 0001124105other
Filed
May 1, 8:00 PM ET
Accepted
May 2, 6:19 PM ET
Size
13.1 KB
Accession
0001140361-24-024125
Insider Transaction Report
Form 4
USMAN NASSIM
DirectorPresident & CEO
Transactions
- Sale
Common Stock
2024-05-01$14.90/sh−5,000$74,500→ 1,736 total - Sale
Common Stock
2024-05-01$15.63/sh−100$1,563→ 1,636 total - Exercise/Conversion
Common Stock
2024-05-01$6.93/sh+20,000$138,600→ 21,636 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-01−20,000→ 281,652 totalExercise: $6.93Exp: 2033-10-31→ Common Stock (20,000 underlying) - Sale
Common Stock
2024-05-01$13.86/sh−14,900$206,514→ 6,736 total
Holdings
- 563(indirect: By Trust)
Common Stock
- 77(indirect: By IRA)
Common Stock
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.50 to $14.44. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.32. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F4]This option is vested in full.
Documents
Issuer
GYRE THERAPEUTICS, INC.
CIK 0001124105
Entity typeother
Related Parties
1- filerCIK 0001206872
Filing Metadata
- Form type
- 4
- Filed
- May 1, 8:00 PM ET
- Accepted
- May 2, 6:19 PM ET
- Size
- 13.1 KB